The biopharmaceutical industry cheered Third Harmonic Bio’s sizeable initial public offering in mid-September but the IPO market in the US has gone quiet since then as broader stock indices – including biotechnology indices and exchange-traded funds – have faltered due to macroeconomic concerns, such as inflation and rising interest rates. Therefore, an alternative to a traditional IPO seems to be gaining momentum once again.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?